Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings, Inc. engages in the development of novel therapies for cancer. The company is headquartered in Rockville, MD.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and is headquartered in Gaithersburg, MD.

There have been plenty of intriguing initial public offerings (IPOs) for investors to follow this year. However, among the most bizarre IPOs of late has been that of Shuttle Pharmaceuticals (NASDAQ: SHPH ).

Shuttle Pharmaceuticals (SHPH) Stock Soars 70% After Its IPO

ROCKVILLE, Md. , Sept. 6, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, today announced the closing of its initial public offering (IPO) of 1,225,888 units of common stock and warrants at a public offering price of $8.125 per unit, for aggregate proceeds of $9,960,340, before deducting underwriting discounts and estimated offering expenses.

Shuttle Pharmaceuticals Announces Closing of Initial Public Offering

The stock price of Shuttle Pharmaceuticals (SHPH) surged by over 350% in its market debut. These are the details.

Shuttle Pharmaceuticals (SHPH) Stock Surges Over 350% In Market Debut: Details

Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effects ROCKVILLE, Md. , Aug. 31, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, is pleased to announce the Company's shares of common stock has commenced trading on The Nasdaq Capital Market under the ticker symbol "SHPH".

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"

ROCKVILLE, Md. , Aug. 30, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, announced today the pricing of its initial public offering of 1,225,888 units of common stock and warrants, which priced at $8.125 per unit, raising gross proceeds of $9,960,340.

Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering

News for Shuttle Pharmaceuticals Holdings Inc Stock (SHPH)